価格表

在庫・価格 : 2024年05月18日 06時04分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-Human SOX17 NL-557 Affinity Purified Polyclonal Ab
データシート※最新のデータシートでない場合があります
NL1924R RSDアールアンドディー システムス
R&D Systems, Inc.
0.5 ml ¥95,000
(未発注)
追加

在庫・価格 : 2024年05月18日 06時04分 現在

Anti-Human SOX17 NL-557 Affinity Purified Polyclonal Ab

  • 商品コード:NL1924R
  • メーカー:RSD
  • 包装:0.5ml
  • 価格: ¥95,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Plachta N et al. Oct4 kinetics predict cell lineage patterning in the early mammalian embryo. Nat. Cell Biol. 2011 Feb;13(2):117-23
Plachta N et al
2011/01/01
Application: IHC Fresh, Sample Type: Whole Tissue PubMed
2 Saini JS et al. Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration. Cell Stem Cell 2017 May;20(5):635-647.e7
Saini JS et al
2017/01/01
Application: ICC, Sample Type: Whole Cells PubMed
3 Riera M et al. Generation of an induced pluripotent stem cell line (FRIMOi002-A) from a retinitis pigmentosa patient carrying compound heterozygous mutations in USH2A gene. Stem Cell Res 2019 03;35:101386
Riera M et al
2019/01/01
PubMed
4 Filimonow K et al. No evidence of involvement of E-cadherin in cell fate specification or the segregation of Epi and PrE in mouse blastocysts. PLoS ONE 2019;14(2):e0212109
Filimonow K et al
2019/01/01
PubMed
5 Riera M et al. Generation of two iPS cell lines (FRIMOi003-A and FRIMOi004-A) derived from Stargardt patients carrying ABCA4 compound heterozygous mutations. Stem Cell Res 2019 Apr;36:101389
Riera M et al
2019/01/01
PubMed
6 Domingo-Prim J et al. Establishment of an induced pluripotent stem cell line (FRIMOi005-A) derived from a retinitis pigmentosa patient carrying a dominant mutation in RHO gene. Stem Cell Res 2019 Jul;38:101468
Domingo-Prim J et al
2019/01/01
PubMed
7 Riera M et al. Establishment and characterization of an iPSC line (FRIMOi001-A) derived from a retinitis pigmentosa patient carrying PDE6A mutations. Stem Cell Res 2019 03;35:101385
Riera M et al
2019/01/01
PubMed
8 Domingo-Prim J et al. Generation of an induced pluripotent stem cell line (FRIMOi007-A) derived from an incomplete achromatopsia patient carrying a novel homozygous mutation in PDE6C gene. Stem Cell Res 2019 10;40:101569
Domingo-Prim J et al
2019/01/01
PubMed
9 Domingo-Prim J et al. Generation of Best disease-derived induced pluripotent stem cell line (FRIMOi006-A) carrying a novel dominant mutation in BEST1 gene. Stem Cell Res 2019 10;40:101570
Domingo-Prim J et al
2019/01/01
PubMed
10 Iannello G et al. Generation of the iPSC line CUIMCi003-A derived from a patient with severe early onset obesity. Stem Cell Res 2021 07;54:102432
Iannello G et al
2021/01/01
Species: Human, Applications: ICC PubMed
  • No.: 1
  • 文献情報:
    Plachta N et al. Oct4 kinetics predict cell lineage patterning in the early mammalian embryo. Nat. Cell Biol. 2011 Feb;13(2):117-23
    Plachta N et al
    2011/01/01
  • 備考:
    Application: IHC Fresh, Sample Type: Whole Tissue
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Saini JS et al. Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration. Cell Stem Cell 2017 May;20(5):635-647.e7
    Saini JS et al
    2017/01/01
  • 備考:
    Application: ICC, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Riera M et al. Generation of an induced pluripotent stem cell line (FRIMOi002-A) from a retinitis pigmentosa patient carrying compound heterozygous mutations in USH2A gene. Stem Cell Res 2019 03;35:101386
    Riera M et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Filimonow K et al. No evidence of involvement of E-cadherin in cell fate specification or the segregation of Epi and PrE in mouse blastocysts. PLoS ONE 2019;14(2):e0212109
    Filimonow K et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Riera M et al. Generation of two iPS cell lines (FRIMOi003-A and FRIMOi004-A) derived from Stargardt patients carrying ABCA4 compound heterozygous mutations. Stem Cell Res 2019 Apr;36:101389
    Riera M et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Domingo-Prim J et al. Establishment of an induced pluripotent stem cell line (FRIMOi005-A) derived from a retinitis pigmentosa patient carrying a dominant mutation in RHO gene. Stem Cell Res 2019 Jul;38:101468
    Domingo-Prim J et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Riera M et al. Establishment and characterization of an iPSC line (FRIMOi001-A) derived from a retinitis pigmentosa patient carrying PDE6A mutations. Stem Cell Res 2019 03;35:101385
    Riera M et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Domingo-Prim J et al. Generation of an induced pluripotent stem cell line (FRIMOi007-A) derived from an incomplete achromatopsia patient carrying a novel homozygous mutation in PDE6C gene. Stem Cell Res 2019 10;40:101569
    Domingo-Prim J et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Domingo-Prim J et al. Generation of Best disease-derived induced pluripotent stem cell line (FRIMOi006-A) carrying a novel dominant mutation in BEST1 gene. Stem Cell Res 2019 10;40:101570
    Domingo-Prim J et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Iannello G et al. Generation of the iPSC line CUIMCi003-A derived from a patient with severe early onset obesity. Stem Cell Res 2021 07;54:102432
    Iannello G et al
    2021/01/01
  • 備考:
    Species: Human, Applications: ICC
  • 参照:
    PubMed